<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" version="2.0">

<channel>
	<title>BioHealth Investor</title>
	
	<link>http://www.biohealthinvestor.com</link>
	<description>Biotech and Medical Business Blog</description>
	<lastBuildDate>Sat, 21 Nov 2009 21:48:45 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" href="http://feeds.feedburner.com/BHI" type="application/rss+xml" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com" /><item>
		<title>Value Stocks in Drugs &amp; Biotech (AMGN, BIIB, CBST, CEPH, PDLI)</title>
		<link>http://www.biohealthinvestor.com/2009/11/value-stocks-in-drugs-biotech-amgn-biib-cbst-ceph-pdli.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/value-stocks-in-drugs-biotech-amgn-biib-cbst-ceph-pdli.html#comments</comments>
		<pubDate>Sat, 21 Nov 2009 21:31:43 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[multiple sclerosis]]></category>
		<category><![CDATA[amgn]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2502</guid>
		
			<content:encoded><![CDATA[This weekend we ran screens of several drug and biotech companies in our quest for &#8216;cheap stocks&#8217; in the BioHealth sector.  The intent is not solely for buyout targets because we prefer to look at value stocks rather than just picking buyout hopefuls.  The obvious issue that makes most of these cheap is because there [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/value-stocks-in-drugs-biotech-amgn-biib-cbst-ceph-pdli.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Activist Going Back After Biogen Idec (BIIB, CELG, GILD, GENZ, AMGN)</title>
		<link>http://www.biohealthinvestor.com/2009/11/activist-going-back-after-biogen-idec-biib-celg-gild-genz-amgn.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/activist-going-back-after-biogen-idec-biib-celg-gild-genz-amgn.html#comments</comments>
		<pubDate>Fri, 20 Nov 2009 16:33:24 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[multiple sclerosis]]></category>
		<category><![CDATA[amgn]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[GILD]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2499</guid>
		
			<content:encoded><![CDATA[Biogen Idec Inc. (NASDAQ: BIIB) is not exactly new to the world of activist investors as there have been problems inside the company for years.  An SEC filing this morning was filed by a fund called HealthCor Management, L.P. located in New York.  It turns out that the fund is not a new entrant here, [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/activist-going-back-after-biogen-idec-biib-celg-gild-genz-amgn.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Share Offerings Weigh on BioHealth Shares</title>
		<link>http://www.biohealthinvestor.com/2009/11/share-offerings-weigh-on-biohealth-shares.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/share-offerings-weigh-on-biohealth-shares.html#comments</comments>
		<pubDate>Fri, 20 Nov 2009 15:30:34 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[BCRX]]></category>
		<category><![CDATA[NVAX]]></category>
		<category><![CDATA[WCRX]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2496</guid>
		
			<content:encoded><![CDATA[Some secondary offerings are good for the existing holders and some are not.  Adding cash to the coffers is good when a company can take advantage of a high share price when they need to raise long-term growth capital.  But there is also the type of secondary offering that is just private equity or private [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/share-offerings-weigh-on-biohealth-shares.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>VIVUS Tapping ED Hurdles (VVUS, PFE, LLY)</title>
		<link>http://www.biohealthinvestor.com/2009/11/vivus-tapping-ed-hurdles-vvus-pfe-lly.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/vivus-tapping-ed-hurdles-vvus-pfe-lly.html#comments</comments>
		<pubDate>Wed, 18 Nov 2009 13:05:24 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[erectile dysfunction]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2493</guid>
		
			<content:encoded><![CDATA[VIVUS Inc. (NASDAQ: VVUS) may soon have a new erectile dysfunction drug on the market if the test results lead to an FDA approval.  Shares are trading higher this morning after it announced positive results in a phase 3 pivotal study evaluating the safety and efficacy of avanafil for the treatment of erectile dysfunction.
If everything [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/vivus-tapping-ed-hurdles-vvus-pfe-lly.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Geron Suppliers Register Shares for Sale (GERN)</title>
		<link>http://www.biohealthinvestor.com/2009/11/geron-suppliers-register-shares-for-sale-gern.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/geron-suppliers-register-shares-for-sale-gern.html#comments</comments>
		<pubDate>Tue, 17 Nov 2009 17:04:02 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[stem cells]]></category>
		<category><![CDATA[GERN]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2491</guid>
		
			<content:encoded><![CDATA[Geron Corp. (NASDAQ: GERN) on Monday filed a registration statement for the resale of shares by existing holders.  This is not a huge deal on the surface as it is &#8216;only&#8217; 344,120 shares of common stock with a listed value of roughly $2 million.  The following share counts are being filed to possibly be sold [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/geron-suppliers-register-shares-for-sale-gern.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Buffett &amp; Berkshire Hathaway BioHealth Stocks (BRK-A, BDX, GSK, JNJ, SNY)</title>
		<link>http://www.biohealthinvestor.com/2009/11/buffett-berkshire-hathaway-biohealth-stocks-brk-a-bdx-gsk-jnj-sny.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/buffett-berkshire-hathaway-biohealth-stocks-brk-a-bdx-gsk-jnj-sny.html#comments</comments>
		<pubDate>Mon, 16 Nov 2009 23:28:14 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[BRK-A]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2488</guid>
		
			<content:encoded><![CDATA[Warren Buffett&#8217;s Berkshire Hathaway Inc. (NYSE: BRK-A) is still a holder of some drug companies and medical devices companies.  Here are the Berkshire Hathaway biohealth positions as of September 30, 2009:

Becton Dickinson &#38; Co. (NYSE: BDX) 1.2 million shares, same as last quarter.
GlaxoSmithkline (NYSE: GSK) 1.51 million shares, same as before.
Johnson &#38; Johnson (NYSE: JNJ) [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/buffett-berkshire-hathaway-biohealth-stocks-brk-a-bdx-gsk-jnj-sny.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Carl Icahn Narrows BioHealth Focus (AMLN, BIIB, ENZN, CYBX, EXEL, FRX, GENZ, REGN)</title>
		<link>http://www.biohealthinvestor.com/2009/11/carl-icahn-narrows-biohealth-focus-amln-biib-enzn-cybx-exel-frx-genz-regn.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/carl-icahn-narrows-biohealth-focus-amln-biib-enzn-cybx-exel-frx-genz-regn.html#comments</comments>
		<pubDate>Mon, 16 Nov 2009 22:50:15 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[EXEL]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[REGN]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2485</guid>
		
			<content:encoded><![CDATA[Carl Icahn, via his Icahn Capital LP and other entities owned the following drug and biotech or biohealth names.  There may be some overlaps because of more than 1 filing, but here goes:
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) 12,971,328 shares;
Biogen Idec Corp. (NASDAQ: BIIB) 3,215,051 shares, second filing showed 12,860,205 shares;
Enzon Pharmaceuticals Inc. (NASDAQ: ENZN) 704,214 [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/carl-icahn-narrows-biohealth-focus-amln-biib-enzn-cybx-exel-frx-genz-regn.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Poniard Becomes Zombie-Risk (PARD)</title>
		<link>http://www.biohealthinvestor.com/2009/11/poniard-becomes-zombie-risk-pard.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/poniard-becomes-zombie-risk-pard.html#comments</comments>
		<pubDate>Mon, 16 Nov 2009 14:43:44 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[fda]]></category>
		<category><![CDATA[PARD]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2482</guid>
		
			<content:encoded><![CDATA[Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) may be done, at least that is how the stock is acting this morning.  The company announced that its pivotal Phase 3 SPEAR trial of picoplatin in the second-line treatment of small cell lung cancer failed to meet its primary endpoint of overall survival. The analysis was based on 320 [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/poniard-becomes-zombie-risk-pard.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nabi Biopharma (NABI): Smoke Gets In Your Eyes: A $500 Million Deal?</title>
		<link>http://www.biohealthinvestor.com/2009/11/nabi-biopharma-nabi-smoke-gets-in-your-eyes-a-500-million-deal.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/nabi-biopharma-nabi-smoke-gets-in-your-eyes-a-500-million-deal.html#comments</comments>
		<pubDate>Mon, 16 Nov 2009 14:32:42 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[R&D]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[NABI]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2479</guid>
		
			<content:encoded><![CDATA[GlaxoSmithKline Biologicals (NYSE:GSK) and Nabi Biopharmaceuticals (NASDAQ:NABI)) today announced an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX(), an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine.
 Under the terms of the agreement [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/nabi-biopharma-nabi-smoke-gets-in-your-eyes-a-500-million-deal.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Genzyme Yells All Clear, Sort Of (GENZ)</title>
		<link>http://www.biohealthinvestor.com/2009/11/genzyme-yells-all-clear-sort-of-genz.html</link>
		<comments>http://www.biohealthinvestor.com/2009/11/genzyme-yells-all-clear-sort-of-genz.html#comments</comments>
		<pubDate>Fri, 13 Nov 2009 22:17:43 +0000</pubDate>
		<dc:creator>247admin</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[fda]]></category>
		<category><![CDATA[GENZ]]></category>

		<guid isPermaLink="false">http://www.biohealthinvestor.com/?p=2476</guid>
		
			<content:encoded><![CDATA[Genzyme Corp. (Nasdaq: GENZ) issued a press release defending itself after such a large stock drop today due to the FDA notice on foreign particles being present in some drugs.
The company announced that it has issued letters to U.S. healthcare providers regarding its enzyme replacement products Cerezyme® (imiglucerase for injection), Fabrazyme® (agalsidase beta), Myozyme® (alglucosidase [...]<br/>
<br/>
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]]]></content:encoded>
			<wfw:commentRss>http://www.biohealthinvestor.com/2009/11/genzyme-yells-all-clear-sort-of-genz.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss><!-- Dynamic page generated in 0.420 seconds. --><!-- Cached page generated by WP-Super-Cache on 2009-11-21 16:48:48 -->
